288 related articles for article (PubMed ID: 19296472)
1. Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo.
Edwards CM; Lwin ST; Fowler JA; Oyajobi BO; Zhuang J; Bates AL; Mundy GR
Am J Hematol; 2009 May; 84(5):268-72. PubMed ID: 19296472
[TBL] [Abstract][Full Text] [Related]
2. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
[TBL] [Abstract][Full Text] [Related]
3. The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo.
Bono C; Karlin L; Harel S; Mouly E; Labaume S; Galicier L; Apcher S; Sauvageon H; Fermand JP; Bories JC; Arnulf B
Haematologica; 2012 Jul; 97(7):1101-9. PubMed ID: 22271897
[TBL] [Abstract][Full Text] [Related]
4. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.
Meister S; Schubert U; Neubert K; Herrmann K; Burger R; Gramatzki M; Hahn S; Schreiber S; Wilhelm S; Herrmann M; Jäck HM; Voll RE
Cancer Res; 2007 Feb; 67(4):1783-92. PubMed ID: 17308121
[TBL] [Abstract][Full Text] [Related]
5. Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells.
Altun M; Galardy PJ; Shringarpure R; Hideshima T; LeBlanc R; Anderson KC; Ploegh HL; Kessler BM
Cancer Res; 2005 Sep; 65(17):7896-901. PubMed ID: 16140960
[TBL] [Abstract][Full Text] [Related]
6. Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.
Catley L; Tai YT; Shringarpure R; Burger R; Son MT; Podar K; Tassone P; Chauhan D; Hideshima T; Denis L; Richardson P; Munshi NC; Anderson KC
Cancer Res; 2004 Dec; 64(23):8746-53. PubMed ID: 15574786
[TBL] [Abstract][Full Text] [Related]
7. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells.
Obeng EA; Carlson LM; Gutman DM; Harrington WJ; Lee KP; Boise LH
Blood; 2006 Jun; 107(12):4907-16. PubMed ID: 16507771
[TBL] [Abstract][Full Text] [Related]
8. Proteasome inhibitor therapy in multiple myeloma.
Chauhan D; Hideshima T; Mitsiades C; Richardson P; Anderson KC
Mol Cancer Ther; 2005 Apr; 4(4):686-92. PubMed ID: 15827343
[TBL] [Abstract][Full Text] [Related]
9. Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib.
Berkers CR; Verdoes M; Lichtman E; Fiebiger E; Kessler BM; Anderson KC; Ploegh HL; Ovaa H; Galardy PJ
Nat Methods; 2005 May; 2(5):357-62. PubMed ID: 15846363
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo.
Navas TA; Nguyen AN; Hideshima T; Reddy M; Ma JY; Haghnazari E; Henson M; Stebbins EG; Kerr I; O'Young G; Kapoun AM; Chakravarty S; Mavunkel B; Perumattam J; Luedtke G; Dugar S; Medicherla S; Protter AA; Schreiner GF; Anderson KC; Higgins LS
Leukemia; 2006 Jun; 20(6):1017-27. PubMed ID: 16617327
[TBL] [Abstract][Full Text] [Related]
11. Quantitative phosphoproteomics of proteasome inhibition in multiple myeloma cells.
Ge F; Xiao CL; Bi LJ; Tao SC; Xiong S; Yin XF; Li LP; Lu CH; Jia HT; He QY
PLoS One; 2010 Sep; 5(9):. PubMed ID: 20927383
[TBL] [Abstract][Full Text] [Related]
12. Sensitizing human multiple myeloma cells to the proteasome inhibitor bortezomib by novel curcumin analogs.
Mujtaba T; Kanwar J; Wan SB; Chan TH; Dou QP
Int J Mol Med; 2012 Jan; 29(1):102-6. PubMed ID: 22012631
[TBL] [Abstract][Full Text] [Related]
13. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.
Hurchla MA; Garcia-Gomez A; Hornick MC; Ocio EM; Li A; Blanco JF; Collins L; Kirk CJ; Piwnica-Worms D; Vij R; Tomasson MH; Pandiella A; San Miguel JF; Garayoa M; Weilbaecher KN
Leukemia; 2013 Feb; 27(2):430-40. PubMed ID: 22763387
[TBL] [Abstract][Full Text] [Related]
14. Noncompetitive modulation of the proteasome by imidazoline scaffolds overcomes bortezomib resistance and delays MM tumor growth in vivo.
Lansdell TA; Hurchla MA; Xiang J; Hovde S; Weilbaecher KN; Henry RW; Tepe JJ
ACS Chem Biol; 2013 Mar; 8(3):578-87. PubMed ID: 23198928
[TBL] [Abstract][Full Text] [Related]
15. The proteasome: a novel target for anticancer therapy.
Montagut C; Rovira A; Albanell J
Clin Transl Oncol; 2006 May; 8(5):313-7. PubMed ID: 16760005
[TBL] [Abstract][Full Text] [Related]
16. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.
Hideshima T; Richardson P; Chauhan D; Palombella VJ; Elliott PJ; Adams J; Anderson KC
Cancer Res; 2001 Apr; 61(7):3071-6. PubMed ID: 11306489
[TBL] [Abstract][Full Text] [Related]
17. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma.
Hideshima T; Bradner JE; Wong J; Chauhan D; Richardson P; Schreiber SL; Anderson KC
Proc Natl Acad Sci U S A; 2005 Jun; 102(24):8567-72. PubMed ID: 15937109
[TBL] [Abstract][Full Text] [Related]
18. Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors.
Cheriyath V; Jacobs BS; Hussein MA
Drugs R D; 2007; 8(1):1-12. PubMed ID: 17249845
[TBL] [Abstract][Full Text] [Related]
19. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
20. In vitro migratory aberrancies of mesenchymal stem cells derived from multiple myeloma patients only partially modulated by bortezomib.
Xu X; Yang J; Tang Y; Li J; Zhu Y; Lu H; Fei X
Int J Clin Exp Pathol; 2014; 7(10):6705-15. PubMed ID: 25400750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]